Q1 Earnings Forecast for AC Immune Issued By HC Wainwright

AC Immune (NASDAQ:ACIU) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of AC Immune in a note issued to investors on Monday, March 16th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.22) for the quarter. The consensus estimate for AC Immune’s current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for AC Immune’s Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.22) EPS.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings results on Friday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. The business had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.14 million. AC Immune had a negative net margin of 1,977.71% and a negative return on equity of 103.15%.

ACIU has been the subject of several other reports. BTIG Research reissued a “buy” rating and issued a $8.00 price target on shares of AC Immune in a report on Monday. Jefferies Financial Group reaffirmed a “buy” rating and set a $7.00 price objective on shares of AC Immune in a report on Friday. Wall Street Zen upgraded AC Immune from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, January 21st. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $9.00.

AC Immune Trading Up 6.1%

Shares of ACIU opened at $3.32 on Tuesday. The stock’s 50 day moving average is $3.14 and its two-hundred day moving average is $3.05. AC Immune has a twelve month low of $1.43 and a twelve month high of $4.00. The firm has a market capitalization of $337.88 million, a PE ratio of -3.95 and a beta of 1.64.

Institutional Investors Weigh In On AC Immune

Several large investors have recently modified their holdings of the stock. Acadian Asset Management LLC lifted its position in shares of AC Immune by 87.1% during the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after buying an additional 172,796 shares during the period. Sei Investments Co. bought a new stake in AC Immune in the second quarter valued at $51,000. Assenagon Asset Management S.A. bought a new stake in AC Immune in the third quarter valued at $549,000. Private Advisor Group LLC acquired a new position in AC Immune during the third quarter worth $48,000. Finally, Susquehanna International Group LLP acquired a new position in AC Immune during the third quarter worth $63,000. 51.36% of the stock is currently owned by institutional investors.

Key Stories Impacting AC Immune

Here are the key news stories impacting AC Immune this week:

• Positive Sentiment: BTIG Research reaffirmed a Buy rating and set an $8.00 price target on ACIU (implies substantial upside vs. the current price), supporting bullish investor sentiment and likely contributing to the stock rise. Benzinga
• Positive Sentiment: Coverage notes (via TipRanks) highlight AC Immune’s advancing neurology pipeline and imminent Alzheimer’s vaccine data — news that can materially re-rate a biotech stock if trial/clinical readouts are positive. TipRanks Article
• Neutral Sentiment: HC Wainwright published updated 2026 quarterly EPS forecasts for ACIU (modeling roughly ($0.22) per quarter and a full‑year loss near ($0.62) EPS). This reiterates expectations of continued losses—important for valuation but not new negative news by itself. MarketBeat
• Neutral Sentiment: Reported short-interest figures in mid-March are effectively zero or show data irregularities (entries list 0 shares and NaN changes). That suggests short interest is not currently a meaningful driver of price action or may reflect reporting/data errors. MarketBeat Short Interest

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.